PanGen Biotech Inc (222110) - Total Liabilities
Based on the latest financial reports, PanGen Biotech Inc (222110) has total liabilities worth ₩2.74 Billion KRW (≈ $1.86 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PanGen Biotech Inc cash conversion from operations to assess how effectively this company generates cash.
PanGen Biotech Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how PanGen Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Check 222110 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
PanGen Biotech Inc Competitors by Total Liabilities
The table below lists competitors of PanGen Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bai Sha Technology Co Ltd
TWO:8401
|
Taiwan | NT$359.65 Million |
|
AC S.A.
WAR:ACG
|
Poland | zł95.32 Million |
|
Sanica Isi Sanayi A.S.
IS:SNICA
|
Turkey | TL2.46 Billion |
|
Duran-Dogan Basim ve Ambalaj Sanayi AS
IS:DURDO
|
Turkey | TL1.36 Billion |
|
Herantis Pharma Oyj
HE:HRTIS
|
Finland | €3.36 Million |
|
REDCO PRP GROUP LTD -05
F:8KI
|
Germany | €45.02 Billion |
|
Finetechnix. Co.Ltd
KQ:106240
|
Korea | ₩47.65 Billion |
|
MCE Holdings Bhd
KLSE:7004
|
Malaysia | RM73.42 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down PanGen Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is PanGen Biotech Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PanGen Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PanGen Biotech Inc (2014–2024)
The table below shows the annual total liabilities of PanGen Biotech Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩5.64 Billion ≈ $3.82 Million |
-31.06% |
| 2023-12-31 | ₩8.18 Billion ≈ $5.54 Million |
+136.67% |
| 2022-12-31 | ₩3.45 Billion ≈ $2.34 Million |
-84.43% |
| 2021-12-31 | ₩22.18 Billion ≈ $15.03 Million |
+0.37% |
| 2020-12-31 | ₩22.10 Billion ≈ $14.98 Million |
+6.98% |
| 2019-12-31 | ₩20.66 Billion ≈ $14.00 Million |
+10.65% |
| 2018-12-31 | ₩18.67 Billion ≈ $12.65 Million |
+335.84% |
| 2017-12-31 | ₩4.28 Billion ≈ $2.90 Million |
+104.76% |
| 2016-12-31 | ₩2.09 Billion ≈ $1.42 Million |
-77.60% |
| 2015-12-31 | ₩9.34 Billion ≈ $6.33 Million |
+50.99% |
| 2014-12-31 | ₩6.18 Billion ≈ $4.19 Million |
-- |
About PanGen Biotech Inc
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, … Read more